{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:56Z","timestamp":1792789676264,"version":"4.5.0"},"reference-count":66,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1\u20133 type-specific and overall, published in the last 10 years. A targeted literature search was conducted across multiple databases from January 2011 to September 2020, including web-based sources and congress proceedings to May 2021. Searches yielded 490 publications, with 31 analyzed: 20 cohort studies (15 prospective, 5 retrospective), 6 cross-sectional studies, 5 online reports (most from Europe (n = 11) or North America (n = 11); one multiregional). Across all GD types, incidence estimates ranged 0.45\u201325.0\/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.45\u201322.9\/100,000 live births (Europe and North America) and GD3: 1.36\/100,000 live births (Asia-Pacific only). GD type-specific prevalence estimates per 100,000 population were GD1: 0.26\u20130.63; GD2 and GD3: 0.02\u20130.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11\u2013139.0\/100,000 inhabitants (17 studies), highest for North America. Generalizability was assessed as \u201cadequate\u201dor \u201cintermediate\u201d for all regions with data. GD incidence and prevalence estimates for the last 10 years varied considerably between regions and were poorly documented outside Europe and North America. Data for GD2 and GD3 were limited.<\/jats:p>","DOI":"10.3390\/jcm12010085","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:26:25Z","timestamp":1671765985000},"page":"85","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-2218","authenticated-orcid":false,"given":"Genaro","family":"Castillon","sequence":"first","affiliation":[{"name":"YolaRX Consultants Inc., Montreal, QC H3H 1V4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-3191","authenticated-orcid":false,"given":"Shun-Chiao","family":"Chang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yola","family":"Moride","sequence":"additional","affiliation":[{"name":"YolaRX Consultants Inc., Montreal, QC H3H 1V4, Canada"},{"name":"Center for Pharmacoepidemiology and Treatment Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: A comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, M., Li, F., Zhang, J., Lu, C., and Kong, W. (2022). Global Epidemiology of Gaucher Disease: An Updated Systematic Review and Meta-analysis. J. Pediatr. Hematol. Oncol.","DOI":"10.21203\/rs.3.rs-982373\/v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_5","first-page":"273","article-title":"Gaucher disease: Insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: A comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","article-title":"Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians","volume":"122","author":"Mehta","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","article-title":"Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention","volume":"82","author":"Mistry","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: Gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet. Test"},{"key":"ref_15","unstructured":"National Organization for Rare Disorders (NORD) (2022, May 13). Rare Disease Database. Available online: https:\/\/rarediseases.org\/rare-diseases\/gaucher-disease\/."},{"key":"ref_16","first-page":"e14422","article-title":"Screening for patients with Gaucher\u2019s disease using routine pathology results: PATHFINDER (ferritin, alkaline phosphatase, platelets) study","volume":"75","author":"Reynolds","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.arcmed.2021.05.001","article-title":"Gaucher Disease: Identification and Novel Variants in Mexican and Spanish Patients","volume":"52","author":"Arreguin","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ddrr.132","article-title":"Expanding newborn screening for lysosomal disorders: Opportunities and challenges","volume":"17","author":"Waggoner","year":"2011","journal-title":"Dev. Disabil. Res. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"136080","DOI":"10.1016\/j.neulet.2021.136080","article-title":"The future of newborn screening for lysosomal disorders","volume":"760","author":"Wasserstein","year":"2021","journal-title":"Neurosci. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ddrr.1117","article-title":"Newborn screening for lysosomal storage disorders and other neuronopathic conditions","volume":"17","author":"Matern","year":"2013","journal-title":"Dev. Disabil. Res. Rev."},{"key":"ref_21","unstructured":"Institute of Medicine (2021, September 25). Standards for Systematic Review. Available online: https:\/\/www.nationalacademies.org\/publications."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13023-014-0134-4","article-title":"The European Gaucher Alliance: A survey of member patient organisations\u2019 activities, healthcare environments and concerns","volume":"9","author":"Niemeyer","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.ymgme.2011.11.038","article-title":"A Pilot Newborn Screening Program for Lysosomal Storage Disorders (LSD) in Illinois","volume":"105","author":"Burton","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-020-1322-z","article-title":"Newborn screening for Morquio disease and other lysosomal storage diseases: Results from the 8-plex assay for 70,000 newborns","volume":"15","author":"Chien","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ymgme.2016.11.152","article-title":"State-wide newborn screening for four lysosomal diseases reveals high incidence rate for Pompe and Fabry diseases","volume":"120","author":"Hopkins","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/jhg.2017.36","article-title":"Successful newborn screening for Gaucher disease using fluorometric assay in China","volume":"62","author":"Kang","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_30","first-page":"S98","article-title":"Selective screening for lysosomal disorders in a large cohort of minority groups shows higher incidence rates and novel variants","volume":"129","author":"Limgala","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ymgme.2019.11.068","article-title":"High incidence of Gaucher disease in northeast Italy: Results from lysosomal newborn screening","volume":"129","author":"Polo","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants","volume":"21","author":"Wasserstein","year":"2019","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/8904_2012_130","article-title":"Newborn screening for lysosomal storage disorders in Hungary","volume":"6","author":"Wittmann","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_35","first-page":"S31","article-title":"Newborn screening for lysosomal disorders in Illinois","volume":"117","author":"Burton","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apa.12807","article-title":"Epidemiology of lysosomal storage diseases in Sweden","volume":"103","author":"Hult","year":"2014","journal-title":"Acta Paediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ymgme.2015.12.193","article-title":"The French Gaucher Disease Registry: Clinical characteristics, complications and treatment of 616 patients","volume":"117","author":"Stirnemann","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","unstructured":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia (SEHH) (2021, May 05). El Retraso en el Diagn\u00f3stico Sigue Siendo un Reto Para el Abordaje de la Enfermedad de Gaucher. Available online: https:\/\/www.sehh.es\/images\/stories\/recursos\/2020\/09\/30\/NdP_Di%CC%81a_Mundial_de_la_Enfermedad_de_Gaucher_2020.pdf."},{"key":"ref_39","first-page":"4","article-title":"Enfermedad de Gaucher en Argentina: Un informe del Registro Internacional de Gaucher y del Grupo Argentino de Diagn\u00f3stico y Tratamiento de la Enfermedad de Gaucher","volume":"17","author":"Drelichman","year":"2013","journal-title":"Hematolog\u00eda"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ymgme.2016.11.130","article-title":"Impact of education and the facilitation of carrier screening in a population at increased risk for lysosomal diseases","volume":"120","author":"Grinzaid","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","first-page":"273","article-title":"Enfermedad de Gaucher en Latinoamerica. Un informe del Registro Internacional y del Grupo Latinoamericano para la Enfermedad de Gaucher","volume":"72","author":"Drelichman","year":"2012","journal-title":"Medicina"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e024251","DOI":"10.1136\/bmjopen-2018-024251","article-title":"Population-based cohort of 500 patients with Gaucher disease in Israel","volume":"9","author":"Jaffe","year":"2019","journal-title":"BMJ Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.29245\/2572-9411\/2018\/2.1148","article-title":"Gaucher Disease in Ontario, Canada: Clinical Manifestations, Natural Progression, and Treatment Response","volume":"3","author":"Yu","year":"2018","journal-title":"J. Rare Dis. Res. Treat."},{"key":"ref_44","first-page":"A34","article-title":"OC-87 Gaucher disease in Romania\u2013baseline characteristics, specific diagnosis, treatment and outcome","volume":"102","author":"Bucerzan","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40200-019-00399-x","article-title":"Healthcare resource utilization and cost of care for Gaucher patients in Iran","volume":"18","author":"Davari","year":"2019","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-7-17","article-title":"Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula","volume":"7","author":"Giraldo","year":"2012","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_47","first-page":"A125","article-title":"P234 Demographic, clinical and genetic characteristics of children with Gaucher disease: The data of paediatric registry in Russia","volume":"102","author":"Movsisyan","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"ref_48","unstructured":"ACOPEL Asociaci\u00f3n Colombiana de Pacientes con Enfermedad Lisosomal (2021, May 01). Validez de la Prueba de Actividad Enzim\u00e1tica de la Glucocerebrosidasa Para el Diagn\u00f3stico de Enfermedad de Gaucher. Available online: https:\/\/docs.bvsalud.org\/biblioref\/2017\/11\/875828\/validez-diagnostica-gaucher.pdf."},{"key":"ref_49","unstructured":"Gauchers Association (2021, May 04). GPnotebook. Gaucher\u2019s Disease (GD). Available online: https:\/\/gpnotebook.com\/simplepage.cfm?ID=-2147090425."},{"key":"ref_50","unstructured":"The National Organization for Rare Disorders (2021, May 03). The Physician\u2019s Guide to Gaucher Disease. Available online: http:\/\/www.filiere-g2m.fr\/fileadmin\/user_upload\/webmasterfichiers\/PNDS___RECO\/NORD_Physician_Guides_Gaucher.pdf."},{"key":"ref_51","unstructured":"L\u2019Institut National D\u2019excellence en Sant\u00e9 et en Services Sociaux (INESSS) (2021, May 03). Avis de Refus D\u2019inscription Aux Listes des M\u00e9dicaments\u2013Valeur Th\u00e9rapeutique. Available online: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Fevrier_2018\/Cerdelga_2018_02.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"PA578","DOI":"10.1016\/j.jval.2016.09.1335","article-title":"A Population-Based Cohort of Gaucher Disease Patients Identified Using EHR Data","volume":"19","author":"Jaffe","year":"2016","journal-title":"Value Health"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mehta, A.B., and Winchester, B. (2022). Newborn Screening for Lysosomal Storage Diseases. Lysosomal Storage Disorders: A Practical Guide, Wiley-Blackwell. [2nd ed.].","DOI":"10.1002\/9781119697312"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Moat, S.J., George, R.S., and Carling, R.S. (2020). Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders. Int. J. Neonatal. Screen, 6.","DOI":"10.3390\/ijns6020026"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100850","DOI":"10.1016\/j.ymgmr.2022.100850","article-title":"Newborn screening for Gaucher disease in Japan","volume":"31","author":"Sawada","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dinur, T., Bauer, P., Beetz, C., Kramp, G., Cozma, C., Iura\u0219cu, M.I., Becker-Cohen, M., Istaiti, M., Rolfs, A., and Zimran, A. (2022). Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031627"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s13023-021-02151-2","article-title":"Gaucher disease: Clinical phenotypes and refining GBA mutational spectrum in Thai patients","volume":"16","author":"Phetthong","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/0883073813515075","article-title":"The relative frequency of lysosomal storage disorders: A medical genetics referral laboratory\u2019s experience from India","volume":"29","author":"Kadali","year":"2014","journal-title":"J. Child Neurol."},{"key":"ref_60","first-page":"13515","article-title":"Gaucher disease: A cause of massive splenomegaly in a 15-year-old black African male","volume":"112","author":"Ramdin","year":"2022","journal-title":"S. Afr. Med. J."},{"key":"ref_61","first-page":"13518","article-title":"Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"112","author":"Sevittz","year":"2022","journal-title":"S. Afr. Med. J."},{"key":"ref_62","first-page":"e17318","article-title":"Gaucher\u2019s Disease in an Adult Female: A Rare Entity","volume":"13","author":"Kannauje","year":"2021","journal-title":"Cureus"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14737159.2018.1495076","article-title":"Digital microfluidics comes of age: High-throughput screening to bedside diagnostic testing for genetic disorders in newborns","volume":"18","author":"Millington","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-022-02192-1","article-title":"Transformative effect of a Humanitarian Program for individuals affected by rare diseases: Building support systems and creating local expertise","volume":"17","author":"Verma","year":"2022","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","article-title":"Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)","volume":"93","author":"Zimran","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100725","DOI":"10.1016\/j.ymgmr.2021.100725","article-title":"The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland","volume":"27","author":"Savolainen","year":"2021","journal-title":"Mol. Genet. Metab. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/85\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:35Z","timestamp":1760147315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010085"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010085","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}